Bexsero

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

31 competitors in Genital Herpes

#DrugCompanyPhaseTrials

1

Famvir

Novartis

Approved

42

Zovirax

BBp Consulting, Inc

Approved

53

Valaciclovir

GSK

Approved

14

Valtrex

GGlaxo Dba Glaxosmithkline

Phase 3

45

Herpes Zoster Vaccine 1437173a

GSK

Phase 3

16

Aciclovir

Sanofi

Phase 3

17

ASP2151

Astellas

Phase 2

18

AIC316

AAiCuris Anti-infective Cures AG

Phase 2

29

Matrix-M2

GGenocea Biosciences, Inc.

Phase 2

110

GEN-003

GGenocea Biosciences, Inc.

Phase 2

1Show 3 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity9 trials

Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults

Completed·CCanadian Immunization Research Network·Phase 4·NCT02583412·120 enrolled

Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04166656·84 enrolled

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

Completed·GSK·Phase 3·NCT02173704·225 enrolled

Show 6 more trials

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Completed·GSK·Phase 2·NCT02212457·1,063 enrolled

A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104

Not yet recruiting·SShanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)·Phase 1·NCT07395739·30 enrolled

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Terminated·Pfizer·Phase 2·NCT04645966·326 enrolled

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Completed·GSK·Phase 1·NCT02491463·73 enrolled

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed·GSK·Phase 3·NCT03621670·1,196 enrolled

Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population

Unknown status·SSt George's, University of London·Phase 4·NCT03682939·55 enrolled

Vaccine1 trial

Meningococcal B Vaccine in Patients with Asplenia

Recruiting·MMedical University of Vienna·Phase 2·NCT06025487·80 enrolled

Women1 trial

BIYELA - Bexsero Immunisation in Young Women in Africa

Active, not recruiting·UUniversity of Washington·Phase 3·NCT06446752·1,100 enrolled

Genital Herpes1 trial

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Completed·Moderna·Phase 1/2·NCT06033261·365 enrolled

Details

Drug Info

Related News